The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting ca...

Full description

Bibliographic Details
Main Authors: Xi Chen, Zhijie Xu, Shuangshuang Zeng, Xiang Wang, Wanli Liu, Long Qian, Jie Wei, Xue Yang, Qiuying Shen, Zhicheng Gong, Yuanliang Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Oncology
Subjects:
nafamostat mesylate
antitumor activities
signaling pathways
efficacy
toxicity
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00852/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00852/full

Similar Items